Results 151 to 160 of about 11,283,677 (180)

Current Status of Molecularly Targeted Therapeutics in Blood Cancers. [PDF]

Int J Mol Sci
Kumala C, Vu L, Fandy TE.
europepmc   +1 more source

Parkinson's Disease Gene Screening in Familial Cases from Central and South America. [PDF]

Mov Disord
Lorenzo-Betancor O, Mehta S, Ramchandra J, Mumuney S, Schumacher-Schuh AF, Cornejo-Olivas M, Sarapura-Castro EH, Torres L, Inca-Martinez MA, Mazzetti P, Cosentino C, Micheli F, Tumas V, Dieguez E, Raggio V, Borges V, Ferraz HB, Chana-Cuevas P, Jimenez-Del-Rio M, Velez-Pardo C, Moreno S, Lopera F, Orozco-Velez JL, Muñoz-Ospina B, Rieder CRM, Medina-Escobar A, Yearout D, Zabetian CP, Mata IF, Latin American Research Consortium on the Genetics of PD (LARGE‐PD).   +29 more
europepmc   +1 more source

The 50th Anniversary Conference - Caxambu 2024. [PDF]

Mem Inst Oswaldo Cruz
Tonelli RR, Lahr DJG, Saraiva EM, Lopes AHCS.   +3 more
europepmc   +1 more source

The African Critical Illness Outcomes Study (ACIOS): a point prevalence study of critical illness in 22 nations in Africa.

Lancet
African Critical Illness Outcomes Study (ACIOS) Investigators.
europepmc   +1 more source

Tratado metódico y práctico de materia médica y de terapéutica fundado en la ley de los semejantes [PDF]

Espanet, Alexis, Hernández y Espeso, Pío   +1 more
core   +1 more source

Diccionario de la lengua castellana [PDF]

Real Academia Española
core   +1 more source

Some of the next articles are maybe not open access.

Related searches:

ZUMA-23: A global, phase 3, randomized controlled study of axicabtagene ciloleucel versus standard of care as first-line therapy in patients with high-risk large B-cell lymphoma.

Journal of Clinical Oncology, 2023
TPS7578 Background: The nearly 40% of patients (pts) with large B-cell lymphoma (LBCL) who are refractory to or relapse after current first-line (1L) standard-of-care (SOC) regimens, such as R-CHOP (rituximab [R] + cyclophosphamide [C], doxorubicin [H ...
J. Westin, C. Jacobson, J. Chavez, A. Sureda, F. Morschhauser, B. Glass, M. Dickinson, A. Davies, I. Flinn, D. Maloney, M. Chamuleau, M. Tees, A. Xue, Shilpa A. Shahani, O. Nikolajeva, Janet Kang, Aida Kaplan, M. Schupp, H. Miao, E. S. Rich   +19 more
semanticscholar   +1 more source

Axicabtagene ciloleucel (axi-cel) in combination with rituximab (Rtx) for the treatment (Tx) of refractory large B-cell lymphoma (R-LBCL): Outcomes of the phase 2 ZUMA-14 study.

Journal of Clinical Oncology, 2022
7567 Background: Despite the success of axi-cel, ≈60% of patients (pts) have no response or relapse within ̃2 y after Tx (Jacobson C, et al. ASH 2021. #1764), highlighting the need for more therapeutic strategies.
P. Strati, L. Leslie, P. Shiraz, L. Budde, O. Oluwole, M. Ulrickson, A. Ramakrishnan, Jennifer Sun, R. Shen, Justyna Kańska, P. McCroskery, Jinghui Dong, M. Schupp, Hairong Xu, K. Patel   +14 more
semanticscholar   +1 more source